Microbot Medical has begun full market release of its Liberty endovascular robotic system in the U.S., it announced at the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto.
Liberty has been used commercially across a range of procedures, including prostate artery embolization, uterine fibroid embolization, genicular artery embolization, Y90 mapping and delivery, and peripheral arterial interventions, according to Microbot. It is the only U.S. Food and Drug Administration (FDA)-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, according to the firm.
In preparation for the full market release, Microbot has expanded its U.S. sales reach from four to eight territories, with a goal of reaching 12 territories by end of 2026.
